The history of angiogenesis inhibitors

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works

Tumor angiogenesis: therapeutic implications

Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · see citing works

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · see citing works

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

OʼReilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,344 · see citing works

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

Yang, J. C., Haworth, L. R., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,681 · see citing works

Transplacental Carcinogenesis by Stilbestrol

Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · see citing works

Thalidomide is an inhibitor of angiogenesis.

D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454 · see citing works

Pegaptanib for neovascular age-related macular degeneration

Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · see citing works

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,932 · see citing works

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · see citing works

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,542 · see citing works

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361 · see citing works

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

Ingber, D. E., Fujita, T., KISHIMOTO, S., Sudo, K., KANAMARU, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,292 · see citing works

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192 · see citing works

Angiostatin induces and sustains dormancy of human primary tumors in mice

O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170 · see citing works

Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy

Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,079 · see citing works

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

Good, D. J., Polverini, P. J., Rastinejad, F., Beau, M. M. L., Lemons, R. S., Frazier, W. A., & Bouck, N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6624 · Cited by 1,051 · see citing works

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039 · see citing works

Disrupting tumour blood vessels

Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1628 · Cited by 931 · see citing works

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

Hanahan, D., Bergers, G., & Bergsland, E. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 868 · see citing works

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 844 · see citing works

Chapter 1: Interferons (IFNs)

(1938), M. F. (1986) · Advances in cancer research · doi:10.1016/s0065-230x(08)60034-2 · Cited by 808 · see citing works

Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts

Inai, T., Mancuso, M. R., Hashizume, H., Baffert, F., Haskell, A., Bałuk, P., Hu‐Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 759 · see citing works

Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides

Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S., Carson, H. F., & Sharpe, R. J. (1990) · Science · doi:10.1126/science.1688470 · Cited by 698 · see citing works

Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone

Folkman, J., Langer, R., Linhardt, R. J., Haudenschild, C. C., & Taylor, S. (1983) · Science · doi:10.1126/science.6192498 · Cited by 619 · see citing works

Protamine is an inhibitor of angiogenesis

Taylor, S., & Folkman, J. (1982) · Nature · doi:10.1038/297307a0 · Cited by 580 · see citing works

Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth

Lawler, J. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00307.x · Cited by 541 · see citing works

Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.

Sidky, Y. A., & Borden, E. C. (1987) · PubMed · Cited by 497 · see citing works

Identification of an Inhibitor of Neovascularization from Cartilage

Moses, M. A., Sudhalter, J., & Langer, R. (1990) · Science · doi:10.1126/science.1694043 · Cited by 478 · see citing works

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 413 · see citing works

Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.

Taraboletti, G., Roberts, D. D., Liotta, L. A., & Giavazzi, R. (1990) · The Journal of Cell Biology · doi:10.1083/jcb.111.2.765 · Cited by 411 · see citing works

Endostatin's Antiangiogenic Signaling Network

Abdollahi, A., Hahnfeldt, P., Maercker, C., Gröne, H., Debus, J., Ansorge, W. J., Folkman, J., Hlatky, L., & Huber, P. E. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00102-9 · Cited by 393 · see citing works

Inhibition of Cell Motility by Interferon

Brouty‐Boyé, D., & Zetter, B. R. (1980) · Science · doi:10.1126/science.6154315 · Cited by 328 · see citing works

Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro.

Iruela‐Arispe, M. L., BORNSTEIN, P. K., & Sage, H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.5026 · Cited by 271 · see citing works

Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.

Kisker, O., Becker, C. M., Prox, D., Fannon, M. W., D’Amato, R. J., Flynn, E. A., Fogler, W. E., Sim, B. K. L., Allred, E. N., Pirie-Shepherd, S. R., et al. (2001) · PubMed · Cited by 257 · see citing works

The Saga of Thalidomide

Mellin, G. W., & Katzenstein, M. (1962) · New England Journal of Medicine · doi:10.1056/nejm196212062672305 · Cited by 252 · see citing works

Endothelial cell proliferation as a novel approach to targeting tumour therapy

Denekamp, J. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.16 · Cited by 249 · see citing works

Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a

Kaban, L. B., Mulliken, J. B., Ezekowitz, R. A. B., Phil, D., Ebb, D. H., Smith, P. S., & Folkman, J. (1999) · PEDIATRICS · doi:10.1542/peds.103.6.1145 · Cited by 245 · see citing works

Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws

Kaban, L. B., Troulis, M. J., Ebb, D. H., August, M. A., Hornicek, F. J., & Dodson, T. B. (2002) · Journal of Oral and Maxillofacial Surgery · doi:10.1053/joms.2002.34975 · Cited by 220 · see citing works

A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids: Induction of Capillary Basement Membrane Dissolution*

Ingber, D. E., Madri, J. A., & Folkman, J. (1986) · Endocrinology · doi:10.1210/endo-119-4-1768 · Cited by 211 · see citing works

Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions

Gasparini, G., Longo, R., Fanelli, M., & Teicher, B. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.022 · Cited by 201 · see citing works

Microvascular Injury in Pathogenesis of Interferon-Induced Necrosis of Subcutaneous Tumors in Mice

Dvorak, H. F., & Gresser, I. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.497 · Cited by 192 · see citing works

Growth Inhibition of Murine Melanoma and Human Colon Carcinoma by Recombinant Human Platelet Factor 4

Sharpe, R. J., Byers, H. R., Scott, C. F., Bauer, S., & Maione, T. E. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.10.848 · Cited by 186 · see citing works

Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors

Sund, M., Hamano, Y., Sugimoto, H., Sudhakar, A., Soubasakos, M. A., Yerramalla, U. L., Benjamin, L. E., Lawler, J., Kieran, M. W., Shah, A. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500180102 · Cited by 182 · see citing works

Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin

Satchi‐Fainaro, R., Mamluk, R., Wang, X., Short, S. M., Nagy, J. A., Feng, D., Dvořàk, A. M., Dvorak, H. F., Puder, M., Mukhopadhyay, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.007 · Cited by 173 · see citing works

Control of tumor growth in animals by infusion of an angiogenesis inhibitor.

Langer, R., Conn, H., Vacanti, J. P., Haudenschild, C. C., & Folkman, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.4331 · Cited by 151 · see citing works

Antiangiogenic Agents in Cancer Therapy

Teicher, B. A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-453-5 · Cited by 122 · see citing works

Differential anticoagulant activity of heparin fragments prepared using microbial heparinase.

Linhardt, R. J., Grant, A., Cooney, C. L., & Langer, R. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34377-1 · Cited by 94 · see citing works

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy

Smith, J. K., Mamoon, N. M., & Duhé, R. J. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000003772462298 · Cited by 94 · see citing works

Inhibition of Development of Murine Melanoma Lung Metastases by Systemic Administration of Recombinant Platelet Factor 4

Kolber, D. L., Knisely, T. L., & Maione, T. E. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.4.304 · Cited by 84 · see citing works

Pulmonary Capillary Hemangiomatosis With Atypical Endotheliomatosis *

Ginns, L. C., Roberts, D. H., Mark, E. J., Brusch, J. L., & Marler, J. J. (2003) · CHEST Journal · doi:10.1378/chest.124.5.2017 · Cited by 62 · see citing works

Therapeutic renaissance of thalidomide in the treatment of haematological malignancies

Ribatti, D., & Vacca, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403852 · Cited by 60 · see citing works

Metronomic Therapy From a Pharmacologist??s View

Kamen, B. A., Glod, J. W., & Cole, P. D. (2006) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200606000-00001 · Cited by 19 · see citing works

Angiogenesis inhibitors revised and revived at AACR

Novak, K. D. (2002) · Nature Medicine · doi:10.1038/nm0502-427 · Cited by 18 · see citing works

TNP-470

Milkowski, D. M., & Weiss, R. A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-453-5_22 · Cited by 6 · see citing works

Adipose tissue remodeling and obesity

Sun, K., Kusminski, C. M., & Scherer, P. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45887 · Cited by 1,941 · see citing works

Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases

Fallah, A., Sadeghinia, A., Kahroba, H., Samadi, A., Heidari, H. R., Bradaran, B., Zeinali, S., & Molavi, O. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.022 · Cited by 259 · see citing works

Suppression of Tumor Growth and Angiogenesis by a Specific Antagonist of the Cell-Surface Expressed Nucleolin

Destouches, D., Khoury, D. E., Hamma‐Kourbali, Y., Krust, B., Albanese, P., Katsoris, P., Guichard, G., Briand, J. P., Courty, J., & Hovanessian, A. G. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002518 · Cited by 153 · see citing works

Therapeutic hydrogel for enhanced immunotherapy: A powerful combination of MnO2 nanosheets and vascular disruption

Wang, D., Feng, C., Xiao, Z., Huang, C., Chen, Z., Fang, W., Ma, X., Wang, X., Luo, L., Hu, K., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101673 · Cited by 44 · see citing works

The past, present, and future of chemotherapy with a focus on individualization of drug dosing

DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 42 · see citing works

History of Research on Angiogenesis

Ribatti, D. (2013) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000353311 · Cited by 26 · see citing works

Anti-angiogenesis in neuroblastoma

Ribatti, D. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.004 · Cited by 24 · see citing works

Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status

Anakha, J., Dobariya, P., Sharma, S. S., & Pande, A. H. (2023) · Medical Oncology · doi:10.1007/s12032-023-02245-w · Cited by 20 · see citing works

The tumor as an organ: comprehensive spatial and temporal modeling of the tumor and its microenvironment

Bloch, N., & Harel, D. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1168-5 · Cited by 16 · see citing works

Review and Comparative Analysis of Machine Learning-based Predictors for Predicting and Analyzing Anti-angiogenic Peptides

Charoenkwan, P., Chiangjong, W., Hasan, M. M., Nantasenamat, C., & Shoombuatong, W. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210810145806 · Cited by 10 · see citing works

The unique signature of tyrosine kinase inhibitor-induced hypothyroidism

Porcelli, T., Stefano, M. A. D., Luongo, C., Schlumberger, M. J., & Salvatore, D. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00193-7 · Cited by 4 · see citing works

GT198 Is a Target of Oncology Drugs and Anticancer Herbs

Pang, J., Gao, J., Zhang, L., Mivechi, N. F., & Ko, L. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.679460 · Cited by 3 · see citing works

Targeting Angiogenesis for Colorectal Cancer Therapy

Gupta, V., Bharmal, T., Dixit, V., Vishvakarma, N. K., Tiwari, A. K., Shukla, D., & Shukla, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-63369-1_11 · Cited by 1 · see citing works

Quantitative In Vivo Assessment of Tumour Vasculature-targeted Liposomes

Dunne, M. (2011) · TSpace (University of Toronto)

Early work on the development of inhibitors of angiogenesis as antitumor agents

Prospero, D. L., Darvishi, S., Perucho, C. E. I., Lopez, V. V., & Francia, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13979-6.00015-7

Anti-Angiogenesis and Vascular Targeting in Tumor Vasculature

Ribatti, D. (2012) · Springer eBooks · doi:10.1007/978-94-007-4936-8_4

History of Research on Tumor Angiogenesis

Ribatti, D. (2008) · Springer eBooks · doi:10.1007/978-1-4020-9563-4 · Cited by 19 · see citing works

Tumor Suppression Through Angiogenesis Inhibition

Arsham, A. M., & Simon, M. C. (2003) · Humana Press eBooks · doi:10.1385/1-59259-329-1:249 · Cited by 1 · see citing works

What tumors need

Epps, H. L. V. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.2017fta · Cited by 3 · see citing works

FROM THE ARCHIVE What tumors need: a brief history of angiogenesis

Heather, T. (2013)